202,907 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 202,907 shares of the specialty pharmaceutical company’s stock, valued at approximately $16,797,000. ANI Pharmaceuticals makes up 1.7% of Parkman Healthcare Partners LLC’s holdings, making the stock its 23rd largest holding.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals during the first quarter worth about $2,706,000. Finally, Norges Bank bought a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $625,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $74.17 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The firm has a 50-day moving average of $80.19 and a 200 day moving average of $78.84. The company has a market cap of $1.70 billion, a P/E ratio of 15.98 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Guggenheim cut their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares in the company, valued at $5,617,523.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. The trade was a 4.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,987 shares of company stock valued at $1,546,405 in the last quarter. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.